What Has Been the Progress and Growth of the Acute Lung Injury Market in Recent Years?
The acute lung injury market has seen considerable growth due to a variety of factors.
• The market size for acute lung injury has experienced consistent growth in the past few years. It is projected to increase from $2.48 billion in 2024 to $2.60 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%.
Factors that contributed to the growth during the historic period include awareness campaigns, a rise in ICU admissions, the effects of smoking and air pollution, infections acquired in hospitals, and initiatives aimed at reducing mortality rates.
What Can Be Expected from the Acute Lung Injury Market in the Coming Years?
The acute lung injury market is expected to maintain its strong growth trajectory in upcoming years.
• In the forthcoming years, the acute lung injury market size is projected to experience consistent growth. By 2029, it is forecasted to reach a value of $3.09 billion, with a compound annual growth rate (CAGR) of 4.4%.
Factors contributing to the predicted growth within this period include, but are not limited to, the advent of biologics and gene therapies, government-funded initiatives and grants, advancements in precision medicine, stem cell therapies and regenerative medicine, along with reforms in global health policy. Future trends within this growth period include the production of biologic drugs, the application of wearable devices for remote monitoring, therapies based on inhalation, the incorporation of CRISPR and gene editing technologies, and the use of biosensors for real-time analysis.
What Are the Critical Driver Fuelling the Acute Lung Injury Market's Growth?
The increasing occurrence of respiratory ailments is poised to push the expansion of the acute lung injury market. These diseases encompass a wide range of conditions impacting the lungs and other respiratory components, resulting in trouble breathing and compromised lung efficiency. The escalating incidences of these diseases may be attributed to the surge in air pollution, tobacco consumption, inactive lifestyles, aging demographics, and viral infection repercussions. Respiratory conditions such as pneumonia induce acute lung injury by instigating excessive inflammation and damaging the alveoli, consequently causing hindered gas exchange and respiratory distress. For example, in September 2023, the Australian Bureau of Statistics, a government agency in Australia, recorded that the death toll from flu and pneumonia in the country climbed from 31.9 per 100,000 individuals in 2021 to 42.6 per 100,000 individuals in 2022, signifying a major increment of nearly 33.54%. As such, the escalating prevalence of respiratory diseases is facilitating the expansion of the acute lung injury market.
How Is the Acute Lung Injury Market segmented?
The acute lung injury market covered in this report is segmented –
1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis
Pre-Book The Acute Lung Injury Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Acute Lung Injury Market?
Top firms in the acute lung injury market are aiming to create innovative treatments, such as peptide treatments, in order to maintain their market stance. Peptide treatment involves the utilization of short sequences of amino acids, or peptides, as healing agents to address health problems. For example, Zuventus Healthcare Ltd., a healthcare firm based in India, unveiled a treatment called Aviptadil in November 2022, aimed to cure acute respiratory distress syndrome (ARDS). This treatment possesses several distinctive benefits, including an extremely potent vasodilatory function that is 50 times more effective than prostacyclin, a lung protective method that encourages surfactant production by binding to alveolar type II cells, anti-inflammatory features that suppress pro-inflammatory cytokines like IL-6 and TNF-alpha, and an immunomodulatory action that manages immune responses in the lungs. Clinical results also display Aviptadil's efficacy in enhancing outcomes for patients struggling with severe virus-related ARDS.
Who Are the Key Players in the Acute Lung Injury Market?
Major companies operating in the acute lung injury market are include:
• Thermo Fisher Scientific Inc.
• GlaxoSmithKline plc
• Medtronic plc
• Baxter International Inc.
• Ono Pharmaceutical Co Ltd.
• Aster DM Healthcare
• Octapharma AG
• Cartesian Therapeutics Inc.
• Vapotherm Inc.
• Stemedica Cell Technologies Inc.
• Implicit Bioscience Ltd.
• Apeiron Biologics AG
• Faron Pharmaceuticals Ltd.
• Histocell Sociedad Limitada
• Vasomune Therapeutics Inc
• Windtree Therapeutics Inc.
• Qx Therapeutics Inc.
• Asklepion Pharmaceuticals LLC
• ReAlta Life Sciences Inc.
• MediciNova Inc.
What Is The Most Dominant Region In The Acute Lung Injury Market?
North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
